---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007972"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:27:02.664884+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial

## Summary
- Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.
- Enrolled first two patients in safety/feasibility Hemopurifier trial for solid tumors at Royal Adelaide Hospital.
- Two Australian sites open; third site ethics approval pending; India site approved at Medanta Medicity.
- James Frakes permanently appointed CEO, previously interim since Nov 2023.
- Operating expenses decreased 9% to $2.9M due to cost-cutting and legal fee reductions.

## SEC filing metadata
- accession: 0001683168-24-007972
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824007972/0001683168-24-007972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824007972/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007972
- JSON: https://secwatch.observer/filing/0001683168-24-007972.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007972.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.